JP Morgan analyst Dae Lee downgrades Offerpad Solutions (NYSE:OPAD) from Overweight to Neutral.
Mustang Bio Announces FDA Acceptance Of IND Application For MB-109, A Novel Combination Of MB-101 And MB-108, For The Treatment Of Recurrent Glioblastoma And High-Grade Astrocytoma
MB‐101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus) are separately well tolerated in patients with recurrent GBM in ongoing Phase 1 clinical trials; preclinical data support potential of
